Reported results
- Total revenue for the three months ended September 30, 2026, was $6.9 million compared to $14.3 million for the three months ended September 30, 2025.
- U.S. YCANTH net product revenue was $5.7 million for the quarter ended September 30, 2026, up 11.9% over the previous quarter and 57.9% year-over-year.
- GAAP net loss was $12.4 million, or $0.58 per share, for the quarter ended September 30, 2026, compared to GAAP net loss of $0.3 million, or $0.03 per share, for the same period in 2025.
- Non-GAAP net loss was $10.5 million, or $0.49 per share, for the quarter ended September 30, 2026, compared to non-GAAP net income of $1.1 million, or $0.12 per share, for the same period in 2025.
- Research and development expenses were $7.6 million for the quarter ended September 30, 2026, compared to $2.2 million for the same period in 2025.
- Selling, general and administrative expenses were $10.4 million for the quarter ended September 30, 2026, compared to $9.4 million for the same period in 2025.
Guidance
- Verrica believes that its cash runway will extend into the fourth quarter of 2027, without giving effect to any potential clinical trial costs related to the study of VP-315 for the treatment of Gorlin syndrome.
- Topline data readouts for the COVE-2 and COVE-3 Phase 3 trials in common warts are expected in the first quarter of 2027 and mid-2027, respectively.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-12 (8-K, Item 2.02). Read the original filing on sec.gov.
